Tag Archive for PRO/AH/EDR> Ebola update (31): Guinea, vaccine

PRO/AH/EDR> Ebola update (31): Guinea, vaccine

Ebola -- GuineaOn [29 May 2020], the European Medicines Agency (EMA) human medicines committee recommended granting Zabdeno and Mvabea a positive opinion for marketing authorizations under exceptional circumstances because the applicant was able to demonstrate that it is not possible to conduct a randomized controlled study that might generate comprehensive clinical data on the efficacy of the latest Ebola vaccine even after authorization.This was considered acceptable in light of the ongoing Ebola Read more [...]